Sat, Feb 28, 2015, 9:55 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

  • snt951 snt951 Oct 28, 2013 11:38 AM Flag

    Lung cancer results

    I am still trying to figure out what happened between the results released Sat. to where it trades today. Do we still have an above average chance to succeed with the Lung Cancer drug or not? Is the increased enrollment and slight delay just a temporary setback? What are the true risks with the hazard ratio? Did the outlier results really hurt our situation?

    Can anybody just break this down in lamens terms please?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I've been following this for a long time and the main red flag that I saw on Sat was the worsening HR coupled with the unusual exclusion of eastern EU sites is very concerning IMO. I still think the best way of playing this stock is with hedged options that limit downside. TO me the play here is still long but the near-term risk is substantial.

      • 1 Reply to shortnstocke
      • Hey, enough of the disinformation. The headline figure given included the outlier eastern EU countries. With those countries excluded, the HR improved significantly.

        And another bit of info for you shorty. There is almost always decay in HR over the course of a study. It is normal. The golden standard for HR is anything with and HR of .80 or better is a slam dunk for approval. Guess what - we are well within the slam dunk zone for approval.

        Facts are facts.

2.40-0.020(-0.83%)Feb 27 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.